

**COMMONWEALTH OF KENTUCKY  
CABINET FOR HEALTH AND FAMILY SERVICES  
DEPARTMENT FOR MEDICAID SERVICES  
PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE MEETING  
Capitol Annex -Room 131**

700 Capital Avenue Frankfort, Kentucky 40601

Thursday, November 16, 2017  
1:00 P.M. to 4:30 P.M.

**AGENDA**

- I. Call to Order and Welcome**
- II. Executive Session** (upon request)
- III. Old Business**
  - a. Approval of Minutes: September 21, 2017 Meeting
  - b. Entresto® Criteria Discussion
- IV. New Business**
  - a. Sedative Hypnotics Maximum Duration Edit
  - b. New Products to Market
    - i. Nerlynx™

*Note: The following new agents will be reviewed along with their respective classes.*

- Syndros™ – Antiemetics and Antivertigo Agents (Delta-9-THC Derivatives)
- Tremfya™ – Cytokine and CAM Antagonists
- Mavyret™ – Hepatitis C Agents (Direct-Acting Antivirals)
- Vosevi™ – Hepatitis C Agents (Direct-Acting Antivirals)
- Idhifa® – Oncology Oral, Hematologic
- Cotempla XR-ODT™ – Stimulants and Related Agents
- Mydayis™ – Stimulants and Related Agents

- V. Therapeutic Classes with Recommended Changes**
  - a. Antiemetics & Antivertigo Agents
    - i. Anti-Emetics: Other
    - ii. Oral Anti-Emetics: 5-HT3 Antagonists
    - iii. Oral Anti-Emetics: Delta-9-THC Derivatives – includes Syndros™
    - iv. Oral Anti-Emetics: NK-1 Antagonists
  - b. Antipsychotics
    - i. First-Generation Antipsychotics
    - ii. Second-Generation Antipsychotics
    - iii. Antipsychotics: Injectables
    - iv. Atypical Antipsychotic and SSRI Combinations
  - c. BPH Treatments
    - i. Alpha Blockers for BPH
    - ii. 5-Alpha Reductase (5AR) Inhibitors
  - d. Cytokine and CAM Antagonists – includes Tremfya™
  - e. H. Pylori Treatment
  - f. Hepatitis C Agents

- i. Direct-Acting Antivirals – includes Mavyret™ and Vosevi™
    - ii. Interferons
    - iii. Ribavirins
  - g. Neuropathic Pain
    - i. Anticonvulsants: Second Generation
    - ii. Antidepressants: SNRIs
  - h. Oncology, Oral – Hematologic – includes Idhifa®
  - i. Stimulants and Related Agents – includes Cotelma XR-ODT™ and Mydayis™

**VI. Consent Agenda**

- a. The following therapeutic classes have no changes recommended and may be voted on as a group under a consent agenda:

Antianginal & Anti-Ischemic	Ophthalmics, Antibiotic-Steroid Combinations
Antibiotics, Topical	Ophthalmics, Antibiotics
Anticoagulants	Ophthalmics, Antivirals
Bronchodilators, Beta-Agonist	Ophthalmics, Glaucoma Agents
Calcium Channel Blockers	Ophthalmics, Mydriatic
Laxatives & Cathartics	Platelet Aggregation Inhibitors
Oncology Oral - Other	Proton Pump Inhibitors
Ophthalmics, Allergic Conjunctivitis	Thrombopoiesis Stimulating Proteins
Ophthalmics, Anti-inflammatories	

- b. The following therapeutic classes have recommended brand/generic switches and may be voted on as a group under a consent agenda:

Antiarrhythmics, Oral	Lipotropics, Other
-----------------------	--------------------

- c. The following therapeutic classes have recommended specific formulation movements and may be voted on as a group under a consent agenda:

N/A
-----

**VII. Adjournment**

- a. Schedule of 2018 Meetings
  - i. **January 18, 2018**
  - ii. **March 15, 2018**
  - iii. **May 17, 2018**
  - iv. **July 19, 2018**
  - v. **September 20, 2018**
  - vi. **November 15, 2018**
- b. Collection of Travel Vouchers

**PUBLIC SPEAKERS:** If you would like to speak during the public session, please complete the Speaker Request Form located on the Committees/P&T tab of the Kentucky specific Magellan Medicaid Administration web portal at:

<https://kyportal.magellanmedicaid.com/provider/public/documents.xhtml>.